Longitudinal profiles of routine serum biomarkers and pain from the nadir through recovery in Guillain–Barré syndrome

Abstract Background Pain is a frequent and disabling manifestation of Guillain–Barré syndrome (GBS), particularly during the acute nadir phase, yet its biological correlates remain poorly understood. Identifying accessible serum biomarkers associated with disease recovery and pain-related outcomes may improve patient monitoring and generate insights into associated mechanisms. Methods A longitudinal analysis of serum biochemical parameters was performed in patients with GBS evaluated at three recovery stages: nadir phase (GBS-T1), onset of recovery (GBS-T2), and late recovery (GBS-T3). Healthy donors and patients with traumatic spinal cord injury (SCI) were included as reference cohorts. Non-parametric statistical analyses were used to identify biomarkers showing recovery-associated changes. Pain intensity, pain interference, and neuropathic pain symptoms were assessed using the Brief Pain Inventory (BPI) and Neuropathic Pain Symptom Inventory (NPSI). Exploratory associations between pain-related outcomes and selected serum biomarkers were assessed using Spearman’s rank correlation. Results Several inflammatory and metabolic biomarkers exhibited stage-dependent changes throughout recovery. C-reactive protein (CRP) and interleukin-6 (IL-6) were highest during GBS-T1 and progressively decreased during recovery, whereas albumin, bilirubin, creatinine, and creatine kinase increased over time. Pain intensity, pain interference, and neuropathic pain symptoms were greatest during GBS-T1 and progressively improved during recovery. At GBS-T1, serum creatinine showed a moderate positive association with pain intensity but did not reach statistical significance (Spearman’s ρ = 0.534, exact two-tailed p = 0.051; n = 14). No significant associations were observed between pain outcomes and C-reactive protein, albumin, bilirubin, or creatine kinase. Conclusions Recovery from the nadir phase of GBS is accompanied by coordinated inflammatory, metabolic, and homeostatic adaptations reflected in circulating serum biomarkers. CRP and IL-6 reflected inflammatory activity, whereas albumin and bilirubin were consistent with restoration of systemic metabolic homeostasis. Serum creatinine showed a moderate but non-significant positive correlation with pain intensity during GBS-T1. This unconfirmed exploratory signal should not be interpreted as evidence that serum creatinine is a biomarker of pain in GBS. Overall, these findings characterize recovery-associated biochemical patterns that warrant further evaluation in larger prospective longitudinal cohorts.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11431023/v1
Primary Topic
Peripheral Neuropathies and Disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Longitudinal profiles of routine serum biomarkers and pain from the nadir through recovery in Guillain–Barré syndrome

Jörg Mey, Javier Parra-Serrano, Maria del Carmen Muñoz‐Turrillas, Antonio Ibarra et al.
Research Square
Peripheral Neuropathies and Disorders
preprint

Longitudinal profiles of routine serum biomarkers and pain from the nadir through recovery in Guillain–Barré syndrome

Jörg Mey, Javier Parra-Serrano, Maria del Carmen Muñoz‐Turrillas, Antonio Ibarra, Ernesto Doncel‐Pérez, Eduardo Vargas‐Baquero, Javier Rodríguez-Gómez, Margarita Villar, Lorenzo Romero‐Ramírez, Carmen Fernández-Alarcón, Raquel Díaz, José de la Fuente, María María Zurdo-López, Javier Blanco-García, Miriam Sagredo del Rio, María Inmaculada Rodríguez-Carrión, Miguel Mas-Serrano, José Rafael Terán-Tinedo, Ángela Beneitez, Carlos Marsal-Alonso
preprint en

Abstract

Abstract Background Pain is a frequent and disabling manifestation of Guillain–Barré syndrome (GBS), particularly during the acute nadir phase, yet its biological correlates remain poorly understood. Identifying accessible serum biomarkers associated with disease recovery and pain-related outcomes may improve patient monitoring and generate insights into associated mechanisms. Methods A longitudinal analysis of serum biochemical parameters was performed in patients with GBS evaluated at three recovery stages: nadir phase (GBS-T1), onset of recovery (GBS-T2), and late recovery (GBS-T3). Healthy donors and patients with traumatic spinal cord injury (SCI) were included as reference cohorts. Non-parametric statistical analyses were used to identify biomarkers showing recovery-associated changes. Pain intensity, pain interference, and neuropathic pain symptoms were assessed using the Brief Pain Inventory (BPI) and Neuropathic Pain Symptom Inventory (NPSI). Exploratory associations between pain-related outcomes and selected serum biomarkers were assessed using Spearman’s rank correlation. Results Several inflammatory and metabolic biomarkers exhibited stage-dependent changes throughout recovery. C-reactive protein (CRP) and interleukin-6 (IL-6) were highest during GBS-T1 and progressively decreased during recovery, whereas albumin, bilirubin, creatinine, and creatine kinase increased over time. Pain intensity, pain interference, and neuropathic pain symptoms were greatest during GBS-T1 and progressively improved during recovery. At GBS-T1, serum creatinine showed a moderate positive association with pain intensity but did not reach statistical significance (Spearman’s ρ = 0.534, exact two-tailed p = 0.051; n = 14). No significant associations were observed between pain outcomes and C-reactive protein, albumin, bilirubin, or creatine kinase. Conclusions Recovery from the nadir phase of GBS is accompanied by coordinated inflammatory, metabolic, and homeostatic adaptations reflected in circulating serum biomarkers. CRP and IL-6 reflected inflammatory activity, whereas albumin and bilirubin were consistent with restoration of systemic metabolic homeostasis. Serum creatinine showed a moderate but non-significant positive correlation with pain intensity during GBS-T1. This unconfirmed exploratory signal should not be interpreted as evidence that serum creatinine is a biomarker of pain in GBS. Overall, these findings characterize recovery-associated biochemical patterns that warrant further evaluation in larger prospective longitudinal cohorts.

Research Square
Consejo Superior de Investigaciones Científicas (ES), Hospital Universitario de Guadalajara (ES), Instituto de Investigación en Recursos Cinegéticos (ES), Universidad Anáhuac (MX), Servicio de Salud de Castilla La Mancha (ES), Hospital Nacional de Parapléjicos (ES), Hospital Universitario de Toledo (ES), University of Castilla-La Mancha (ES)
Good health and well-being
Peripheral Neuropathies and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon